The use of immunotherapy in patients with various types of cancer has led to dramatic increases in survival. Increased median ...

Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved ...

On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients ...

Libtayo is approved for adjuvant treatment in high-risk CSCC patients post-surgery and radiation, showing significant disease-free survival benefits in the C-POST trial. The C-POST trial excluded ...

Please provide your email address to receive an email when new articles are posted on . A genomic test predicts individual risk for metastasis after a cutaneous squamous cell carcinoma diagnosis. Two ...

Hernexeos (zongertinib) received FDA accelerated approval for unresectable or metastatic non-squamous NSCLC with HER2 TKD mutations after prior treatment. The Beamion LUNG-1 trial showed a 75% ...

Comparing metagenomic profiles of the skin microbiome in immunosuppressed patients and those at high and low risk for cutaneous squamous cell carcinoma (SCC) revealed distinct expansions in fungal and ...

According to global epidemiological data, laryngeal cancer, a major type of malignant head and neck tumor, accounts for approximately 1% of all malignant tumors (1). Approximately 90% of the ...

Doctors at the National Institutes of Health have discovered a new cause of skin cancer, according to a case report published Wednesday in the New England Journal of Medicine. The culprit is a type of ...

Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and β-human papillomavirus (β-HPV) is believed to be a mere facilitator that is ...

Penile cancer is a rare malignancy, the most common subtype of which is squamous cell carcinoma (SCC). Organ-sparing surgery (OSS) is the first-line treatment for early-stage tumors given the ...